FMT

Disclaimer; We are still far from understanding these 2 cases, and FMT is only for #cdiff. These 2 cases, which have not been reproduced yet, open a possibility that there may be such a thing as a donor who carries microbes that allow hair growth… OR NOT… Welcome to research…… https://t.co/UY51JkwkVJ— sabine hazan md (@SabinehazanMD) March 14, 2023

And now - a chance to hear about #FMT directly from @HassaneZarour. As he highlights papers from @diwakardavar & #Baruch in @ScienceMagazine, he points out key differences in donors, sample prep, etc. FMT caps from @BertrandRouty & novel tx from @MaaT_Pharma also of interest. pic.twitter.com/qr2ApDOgNt— Sumanta K. Pal, MD, FASCO (@montypal) March 11, 2023

@rupertleong shows the different strategies to improve outcomes of #FMT in #ulcerativecolitis #GMFH2023 #microbiomeclinicians pic.twitter.com/ki1KuRHMbr— Gianluca Ianiro (@gianluca1aniro) March 11, 2023

“C difficile in patients with IBD is difficult to handle. We here suggest a therapeutic approach, based on Danish-Dutch-French-German-Italian experiences with FMT for patients with IBD and C difficile. @SMDBaunwall @h_sokol @mjvehreschild @gianluca @EMTerveer @AUHdk @HepGas”

Faecal 🦠microbiota transplantation (#FMT), short-term dietary manipulation of #tryptophan & oral 3-IAA administration ↘️Is it the near future in therapy🦠of Pancreatic Ductal Adenocarcinoma (#PDAC) which is expected to be the 2nd most deadly🦞by 2040❓https://t.co/j3X71Smqwp https://t.co/Iu7Zg2T8RK— Robert Dudkowiak MD, PhD (@drRobinDud) March 13, 2023

@madsen_ca talking about combining fibers with #Fmt in metabolic syndrome #GMFH2023 pic.twitter.com/HQ6CfnVULu— Harry Sokol (@h_sokol) March 11, 2023

FMT should be considered as a chronic treatment. Gianluca Ianiro @gianluca1aniro #GMFH2023 #gutmicrobiota pic.twitter.com/C8HByXUTTU— Microbiota and Host (@MicrobiotaHost) March 11, 2023

The results show concomitant recurrent CDI was associated with an IBD flare in 54% of participants. Of this group, 63% received IBD remission-induction therapy before FMT.

FMT for rCDI in IBD patients is safe and effective, and IBD exacerbation after FMT is infrequent. Further studies should investigate the effects on IBD course following FMT.

FMT for rCDI in IBD patients is safe and effective, and IBD exacerbation after FMT is infrequent. Further studies should investigate the effects on IBD course following FMT.

Although antibiotics are an effective treatment option, evidence indicates that fecal microbiota transplant holds promise in treating refractory or recurrent C difficile infections.

#MEAwarenessHour“A study undertaken in a single centre in Australia has already reported significant clinical improvement in 70% of #MECFS patients administered an FMT."#pwME #MyalgicEncephalomyelitis— Let's Do It for ME! (@LetsDoIt4ME) March 1, 2023

FMT has been approved for treatment of C. difficile infection in the U.S. and has shown early promise for some categories of #IBD. We eagerly await large-scale clinical trials that will provide more insight.#crohns #crohnsdisease #inflammatoryboweldisease #FMT pic.twitter.com/0oNUl3jqrp— Propel a Cure for Crohn’s Disease (@propelacure) March 9, 2023

We found that higher residual alpha diversity and Lactobacillus blooms after antibiotic treatment correlated with improved engraftment and clinical response to FMT. Future studies should closely examine the host microbial communities pre-FMT and the impact of antibiotic preconditioning on engraftmen …

Fecal Microbiota Transplants in the Context of (Child and Adolescent) Psychiatric Disorders Abstract: There has recently been a significant increase in interest in gut microbiota and its interaction with the brain (gut-brain axis). Not only are the findings of microbiome research interesting …

Live fecal microbiota (Rebyota) for prevention of CDI recurrence

Transplantation précoce de microbiote fécal dans l’infection à Clostridioides difficile

How to ( and can we ?) achieve eubiosis in #IBD @JordiGuardiolac with a brilliant talk on all approaches including #FMT ▶️here already but May not ready for prime time ▶️Need more studies on donor-recipient matching ▶️Combination treatment approaches ▶️Better delivery pic.twitter.com/elf5AnhcDB— Seb (@ibdseb) March 1, 2023

This article covers major challenges for the treatment in transitioning from bench to bedside, from the scientific, clinical and regulatory perspectives

The intestinal microbiota plays an important role in maintaining human health, and its alteration is now associated with the development of various gastrointestinal (ulcerative colitis, irritable bowel syndrome, constipation, etc.) and extraintestinal diseases, such as cancer, metabolic syndrome, neuropsychiatric diseases. In this context, it is not surprising that gut microbiota modification methods may constitute a therapy whose potential has not yet been fully investigated. In this regard, the most interesting method is thought to be fecal microbiota transplantation, which consists of the simultaneous replacement of the intestinal microbiota of a sick recipient with fecal material from a healthy donor. This review summarizes the most interesting findings on the application of fecal microbiota transplantation in gastrointestinal and extraintestinal pathologies.

GuruFocus Article or News written by Business Wire and the topic is about:

Congratulations to @DylanFortman, star @PittIMChiefs whose work on costs of #FMT to treat I/O-refractory #melanoma was just published. This work provides clarify on the feasibility of establishing fecal biobanks for indications other than rCDI. @UPMCHillmanCC pic.twitter.com/AJj13zzUOZ— Diwakar Davar, M.D. (@diwakardavar) February 27, 2023

Learn about fecal transplant or bacteriotherapy, a procedure that may help treat gut infections, ulcerative colitis, and other diseases.

Fecal microbiota transplantation (FMT) is the process of transplanting stool from a healthy donor into the gut of a patient for therapeutic purposes. Current guidelines recommend FMT for the prevention of multiply recurrent Clostridioides difficile infection (CDI) after two recurrences, with …

The bulletproof glass was broken. 500k+ stool-donor applicants came flooding through.

Fecal microbiota transplantation (FMT) is currently considered a potential treatment for various GI-related illnesses, with the goal to replenish natural healthy flora of the GI tract that has b...

Background Gamma-delta (γδ) T cells are a major cell population in the intestinal mucosa and are key mediators of mucosal tolerance and microbiota composition. Little is known about the mechanisms by which intestinal γδ T cells interact with the gut microbiota to maintain tolerance. Results We found that antibiotic treatment impaired oral tolerance and depleted intestinal γδ T cells, suggesting that the gut microbiota is necessary to maintain γδ T cells. We also found that mice deficient for γδ T cells (γδ−/−) had an altered microbiota composition that led to small intestine (SI) immune dysregulation and impaired tolerance. Accordingly, colonizing WT mice with γδ−/− microbiota resulted in SI immune dysregulation and loss of tolerance whereas colonizing γδ−/− mice with WT microbiota normalized mucosal immune responses and restored mucosal tolerance. Moreover, we found that SI γδ T cells shaped the gut microbiota and regulated intestinal homeostasis by secreting the fecal micro-RNA let-7f. Importantly, oral administration of let-7f to γδ−/− mice rescued mucosal tolerance by promoting the growth of the γδ−/−-microbiota-depleted microbe Ruminococcus gnavus. Conclusions Taken together, we demonstrate that γδ T cell-selected microbiota is necessary and sufficient to promote mucosal tolerance, is mediated in part by γδ T cell secretion of fecal micro-RNAs, and is mechanistically linked to restoration of mucosal immune responses. Video Abstract

The gut microbiome acts as a tumor-extrinsic regulator of responses to immune-checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors. Primary resistance to anti-PD-1 ICI can be reversed via responder-derived fecal microbiota transplant (FMT) in patients with refractory melanoma. Efforts to …

The Medical Letter has provided trusted prescription drug information and drug facts since 1959